Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | M1774 + PLX038 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M1774 | M-1774|M 1774|tuvusertib | ATR Inhibitor 16 | M1774 is an ATR inhibitor, which potentially decreases tumor growth (Cancer Res (2022) 82 (12_Supplement): 2588). | |
PLX038 | PLX038A|PLX-038|PLX 038 | TOPO Inhibitor (Pan) 3 | PLX038 is a PEG-conjugated form of the topoisomerase inhibitor SN-38 (PMID: 31707444). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06337630 | Phase I | M1774 + PLX038 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (POP-ART) | Not yet recruiting | FRA | 0 |